DiaMedica Therapeutics
DMAC
DMAC
32 hedge funds and large institutions have $12.7M invested in DiaMedica Therapeutics in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
16% less funds holding
Funds holding: 38 → 32 (-6)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Holders
32
Holding in Top 10
–
Calls
$33K
Puts
$8K
Top Buyers
| 1 | +$2.04M | |
| 2 | +$585K | |
| 3 | +$503K | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$56.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.33K |
Top Sellers
| 1 | -$817K | |
| 2 | -$417K | |
| 3 | -$81.9K | |
| 4 |
AAS
Avantax Advisory Services
Dallas,
Texas
|
-$35.5K |
| 5 |
Bank of New York Mellon
New York
|
-$28.3K |